Tweet
Shares of Denali Therapeutics Inc (NASDAQ:DNLI) have been given an average rating of "Hold" by the six brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $24.00.
DNLI has been the subject of a number of recent research reports. ValuEngine upgraded Denali Therapeutics from a "sell" rating to a "hold" rating in a research note on Wednesday, May 2nd. Zacks Investment Research lowered Denali Therapeutics from a "hold" rating to a "sell" rating in a research note on Tuesday. Get Denali Therapeutics alerts:
DNLI opened at $16.17 on Tuesday. Denali Therapeutics has a 1-year low of $12.32 and a 1-year high of $25.79. The company has a market capitalization of $1.43 billion and a PE ratio of -2.75.
Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Thursday, August 9th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.39). The firm had revenue of $1.65 million during the quarter, compared to the consensus estimate of $3.00 million. sell-side analysts anticipate that Denali Therapeutics will post -0.74 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Denali Therapeutics in the first quarter valued at $142,000. Trexquant Investment LP acquired a new position in shares of Denali Therapeutics in the second quarter valued at $155,000. New York State Common Retirement Fund acquired a new position in shares of Denali Therapeutics in the first quarter valued at $173,000. D.A. Davidson & CO. acquired a new position in shares of Denali Therapeutics in the first quarter valued at $197,000. Finally, American International Group Inc. acquired a new position in shares of Denali Therapeutics in the first quarter valued at $203,000. Institutional investors and hedge funds own 64.00% of the company's stock.
About Denali Therapeutics
Denali Therapeutics, Inc engages in the development of portfolio of therapeutic candidates for neurodegenerative diseases. Its programs comprises of lysosomal function pathway, glial biology pathway, and cellular homeostasis. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth in 2013 and is headquartered in San Francisco, CA